• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

anti-F9 antibody :: Sheep Factor IX Polyclonal Antibody

Scan QR to view Datasheet
Catalog # MBS512036
Unit / Price
Scan QR to view Datasheet
  0.5 mg  /  $440 +1 FREE 8GB USB
anti-F9 antibody
Product Name

Factor IX (F9), Polyclonal Antibody

Full Product Name

Sheep anti-human Factor IX (F.IX), Affinity-Purified IgG

Product Synonym Names
Factor IX, human
Product Gene Name
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
Chromosome Location
Chromosome: X; NC_000023.10 (138612895..138645617). Location: Xq27.1-q27.2
3D Structure
ModBase 3D Structure for P00740
This antibody is specific for F.IX as demonstrated by immunoelectrophoresis and ELISA.
Affinity purified IgG.
Vial containing ml of IgG purified by affinitychromatography on immobilized F.IX. Total protein is 0.5 mg.
Affinity-purified IgG (APIgG), clear liquid.
APIgG concentration is mg/ml, determined by absorbance using an extinction coefficient (E1%280) of 13.4. (lot specific)
Human Factor IX purified from plasma.
10 mM HEPES, pH 7.4, 150 mM NaCl, 50% (v/v) glycerol.
Neutralizing Activity
XXXX Bethesda Units/ml IgG against normal plasma. One Bethesda unit/ml is defined as the amount of inhibitor that resulted in 50% residual F.IX activity after 2 hours at 37 degree C (Kasper CK et al, Thromb Diath Haemorrh 34:869, 1975).
Preparation and Storage
Store between -10 and -20 degree C. Product will become viscous but will not freeze. Avoid storage in frost-free freezers. Keep vial tightly capped. Allow product to warm to room temperature and gently mix before use.
Other Notes
Small volumes of anti-F9 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
anti-F9 antibody
Factor IX (F.IX, Christmas Factor) is a vitamin K-dependent glycoprotein produced in the liver. Plasma concentration of F.IX is normally around 5 ug/ml (87 nM) in plasma. The biological importance of F.IX is demonstrated in Haemophilia B (Christmas disease), an X-linked congenital bleeding disease resulting from a quantitative (low activity and low antigen) or qualitative (low activity and normal antigen) defect in F.IX function. In its proenzyme or zymogen form F.IX is a single chain molecule of 55,000 daltons. It contains two EGF-like domains and an amino-terminal domain containing 12 gamma-carboxy-glutamic acid (Gla) residues. These Gla residues allow F.IX to bind divalent metal ions and participate in calcium-dependent binding interactions. The activation of F.IX occurs by limited proteolysis in the presence of calcium by activated factor XI (FXIa) and/or by a complex of VIIa/tissue factor/phospholipid and activated Factor X between residues Arg146-Ala147 and between Arg180-Val181. The terminal activated product in either case is F.IXabeta, a two-chain enzyme consisting of a heavy chain (28,000 daltons), a light chain (18,000 daltons) and an activation peptide product of 11,000 daltons. F.IX can also be cleaved into inactive products by thrombin and by elastase. The activity of F.IXabeta in plasma is inhibited by antithrombin and this inhibition is accelerated 1000-fold in the presence of optimal concentrations of heparin 1-3.
Application Notes for anti-F9 antibody
Suitable as a source of enriched antibodies to F.IX.
NCBI/Uniprot data below describe general gene information for F9. It may not necessarily be applicable to this product.
UniProt Primary Accession #
UniProt Secondary Accession #
UniProt Related Accession #
Molecular Weight
51,778 Da[Similar Products]
NCBI Official Full Name
factor IX
NCBI Official Synonym Full Names
coagulation factor IX
NCBI Official Symbol
NCBI Official Synonym Symbols
FIX; P19; PTC; HEMB; MGC129641; MGC129642
  [Similar Products]
NCBI Protein Information
coagulation factor IX; FIX F9; factor 9; Christmas factor; OTTHUMP00000024154; plasma thromboplastic component; plasma thromboplastin component
UniProt Protein Name
Coagulation factor IX
UniProt Synonym Protein Names
Christmas factor; Plasma thromboplastin component
Protein Family
UniProt Gene Name
UniProt Entry Name
NCBI Summary for F9
This gene encodes vitamin K-dependent coagulation factor IX that circulates in the blood as an inactive zymogen. This factor is converted to an active form by factor XIa, which excises the activation peptide and thus generates a heavy chain and a light chain held together by one or more disulfide bonds. The role of this activated factor IX in the blood coagulation cascade is to activate factor X to its active form through interactions with Ca+2 ions, membrane phospholipids, and factor VIII. Alterations of this gene, including point mutations, insertions and deletions, cause factor IX deficiency, which is a recessive X-linked disorder, also called hemophilia B or Christmas disease. [provided by RefSeq]
UniProt Comments for F9
Function: Factor IX is a vitamin K-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor X to its active form in the presence of Ca2+ ions, phospholipids, and factor VIIIa.

Catalytic activity: Selective cleavage of Arg-|-Ile bond in factor X to form factor Xa.

Subunit structure: Heterodimer of a light chain and a heavy chain; disulfide-linked.

Subcellular location: Secreted.

Tissue specificity: Synthesized primarily in the liver and secreted in plasma.

Domain: Calcium binds to the gamma-carboxyglutamic acid (Gla) residues and, with stronger affinity, to another site, beyond the Gla domain.

Post-translational modification: Activated by factor XIa, which excises the activation peptide.The iron and 2-oxoglutarate dependent 3-hydroxylation of aspartate and asparagine is (R) stereospecific within EGF domains.

Involvement in disease: Defects in F9 are the cause of recessive X-linked hemophilia B (HEMB) [

MIM:306900]; also known as Christmas disease. Ref.11 Ref.13 Ref.34 Ref.37 Ref.38 Ref.39 Ref.40 Ref.41 Ref.42 Ref.43 Ref.44 Ref.45 Ref.46 Ref.47 Ref.48 Ref.49 Ref.50 Ref.51 Ref.52 Ref.53 Ref.54 Ref.55 Ref.56 Ref.57 Ref.58 Ref.59 Ref.60 Ref.62 Ref.63 Ref.64 Ref.65 Ref.66 Ref.67 Ref.70 Ref.71 Ref.72Note=Mutations in position 43 (Oxford-3, San Dimas) and 46 (Cambridge) prevents cleavage of the propeptide, mutation in position 93 (Alabama) probably fails to bind to cell membranes, mutation in position 191 (Chapel-Hill) or in position 226 (Nagoya OR Hilo) prevent cleavage of the activation peptide.Defects in F9 are the cause of thrombophilia due to factor IX defect (THR-FIX) [

MIM:300807]. A hemostatic disorder characterized by a tendency to thrombosis. Ref.73

Pharmaceutical use: Available under the name BeneFix (Baxter and American Home Products). Used to treat hemophilia B.

Miscellaneous: In 1952, one of the earliest researchers of the disease, Dr. R.G. Macfarlane used the patient's surname, Christmas, to refer to the disease and also to refer to the clotting factor which he called the 'Christmas Factor' At the time Stephen Christmas was a 5-year-old boy. He died in 1993 at the age of 46 from acquired immunodeficiency syndrome contracted through treatment with blood products.

Sequence similarities: Belongs to the peptidase S1 family.Contains 2 EGF-like domains.Contains 1 Gla (gamma-carboxy-glutamate) domain.Contains 1 peptidase S1 domain.
Product References and Citations for anti-F9 antibody
1. Lawson, JH, Mann KG; Cooperative Activation of Human F.IX by the Human Extrinsic Pathway of Coagulation; JBC 266 pp11317-11327, 10991.
2. Enfield DL, Thompson AR; Cleavage and Activation of Factor IX by Serine Proteases; Blood 64, pp 821-831, 1984.
3. Limentani SA, Furie BC, Furie B, in Hemostasis and Thrombosis, 3rd Edition, eds. RW Colman, J Hirsh, VJ Marder and EW Salzman, pp. 94-108, J.B. Lippincott Co., Philadelphia PA, USA, 1994.

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated with anti-F9 antibody
 Reference Product  PubMed Publications
 GGCX antibody  >1 publications with F9 and GGCX
Organs/Tissues associated with anti-F9 antibody
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

Contact Us

Please fill out the form below and our representative will get back to you shortly.